Marked increase in steady-state serum levels achieved with itraconazole oral solution compared with capsule formulation.

1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006. 2. Arpin C, Dubois V, Coulange L et al. Extended-spectrum b-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003; 47: 3506–14. 3. De Gheldre Y, Avesani V, Berhin C et al. Evaluation of Oxoid combination discs for detection of extended-spectrum b-lactamases. J Antimicrob Chemother 2003; 52: 591–7. 4. Jeong SH, Bae IK, Kwon SB et al. Dissemination of transferable CTX-M-type extended-spectrum b-lactamase-producing Escherichia coli in Korea. J Appl Microbiol 2005; 98: 921–7. 5. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657–86. 6. Pitout JD, Nordmann P, Laupland KB et al. Emergence of Enterobacteriaceae producing extended-spectrum b-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52–9. 7. Rodriguez-Bano J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum b-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089–94. 8. Valverde A, Coque TM, Sanchez-Moreno MP et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum b-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769–75. 9. Andres P, Petroni A, Faccone D et al. Extended-spectrum b-lactamases in Shigella flexneri from Argentina: first report of TOHO-1 outside Japan. Int J Antimicrob Agents 2005; 25: 501–7. 10. Kim S, Kim J, Kang Y et al. Occurrence of extended-spectrum b-lactamases in members of the genus Shigella in the Republic of Korea. J Clin Microbiol 2004; 42: 5264–9.